English: Erythematous rash in the pattern of a “bull’s-eye” from Lyme disease (Photo credit: Wikipedia)
Reported in The Lancet, results on 300 tested revealed strong immune response to the vaccine
The results of a phase 1/2 clinical trial in Europe of an investigational Lyme disease vaccine co-developed by researchers at Stony Brook University, Brookhaven National Laboratory, and at Baxter International Inc., a U.S. based healthcare company, revealed it to be promising and well tolerated, according to a research paper published online in The Lancet Infectious Diseases. The vaccine was shown to produce substantial antibodies against all targeted species of Borrelia, the causative agent of Lyme disease in Europe and the United States. Baxter International conducted the clinical trial of the vaccine.
Since the early 1990s, Benjamin Luft, MD, the Edmund D. Pellegrino Professor of Medicine at Stony Brook University School of Medicine, and the late John Dunn, Ph.D., a biologist at Brookhaven National Laboratory, spearheaded the initial development of the original vaccine antigen concept, and together with researchers at Baxter International helped bioengineer the formulation used in the clinical trial. Through the Stony Brook University School of Medicine and Brookhaven National Laboratory, The Research Foundation of the State of New York licensed intellectual property of the Lyme vaccine technology to Baxter International. Baxter International researchers in collaboration with Luft and Dunn developed further innovations employed in the Lyme vaccine used in the clinical trial.
In the article, “Safety and immunogenicity of a novel multivariant OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomized, dose-escalation phase 1/2 trial,” Principal Investigator P. Noel Barrett, PhD, of Baxter, Biomedical Research Centre, and co-authors evaluated the safety and immunogenicity of the vaccine in a range of doses in 300 people living in Austria and Germany. Study participants received three primary immunizations and one booster immunization. All doses and formulations, some of which included an adjuvant, an additive to stimulate immune response to the vaccine, induced substantial antibody titers against all species of Borrelia. The vaccine demonstrated predominantly mild adverse reactions and no-vaccine related serious events occurred in the sample population.
“The results of the clinical trial conducted by Baxter are promising because the vaccine generated a potent human immune reaction, covered the complete range of Borrelia active in the entire Northern hemisphere, and produced no major side effects,” said Dr. Luft, a co-author on the paper. “We hope that a larger-scale, Phase 3 trial will demonstrate not only a strong immune response but true efficacy in a large population that illustrates protection against Lyme disease.”
The Latest Bing News on:
Lyme Disease Vaccine
- Lyme Disease Research and Advocacy: The Pandemic Does Not Slow Them Downon January 20, 2021 at 1:53 am
Lyme disease research and advocacy efforts forged ahead and made some exciting advances in 2020 despite a pandemic that presented numerous challenges, delays and roadblocks in many areas of medical ...
- Policy Pennings: Preparing for zoonotic diseaseson January 13, 2021 at 9:30 am
The approval of Emergency Use Authorizations for COVID-19 vaccines is an important step in bringing the pandemic under control.
- VERIFY: Do you need the COVID-19 vaccine every year? It's too early to knowon January 12, 2021 at 2:52 pm
A viewer wanted to know if the COVID-19 vaccine, like the flu vaccine, is an annual shot. GREENSBORO, N.C. — As thousands of Americans across the country urgently line up to roll up their sleeves, ...
- Telehealth, drug prices, vaccine rollout headline day 2 of JPMorgan Healthcare Conferenceon January 12, 2021 at 2:22 pm
Not surprisingly, vaccine rollout and distribution was a major focus on the second day of the 39 th annual JPMorgan Healthcare Conference. But the day’s sessions touched on several other themes of ...
- A future of infectious diseaseon January 7, 2021 at 2:19 pm
Or more recently reforestation in the north-eastern part of the USA led to Lyme Disease when reforestation schemes provided a fertile environment for people, deer and a deer-borne tick to interact. In ...
- Valneva Reports FY 2020 Cash of Over €200 Millionon January 7, 2021 at 9:46 am
Valneva’s cash and cash equivalents at December 31, 2020 increased to €204.4 million compared to €64.4 million at December 31, 2019. The change was primarily driven by a $130.0 million upfront payment ...
- Living Lab Radio: A Lyme Disease Vaccine Edges Closer To Reality, 100 Nuclear Bombs Is Enough, And Moreon December 29, 2020 at 2:03 am
It’s hard to believe, but we actually had a vaccine for Lyme disease in the 1990s. It was pulled from the market in 2002 after a class action lawsuit alleged that it infected people with Lyme rather ...
- Anwar Hadid says he 'absolutely' won't take the COVID-19 vaccine and defends himself amid backlash from fanson December 28, 2020 at 2:01 pm
She called Lyme disease an "invisible disease," adding that ... While some people have expressed caution about taking the COVID-19 vaccine,health officials strongly urged people to receive ...
The Latest Google Headlines on:
Lyme Disease Vaccine
The Latest Bing News on:
Lyme Disease
- Mariia Tsegelnyk’s Take on How She Transformed Her Obstacles into Her Superpowerson January 19, 2021 at 8:26 am
Mariia Tsegelnyk, a young entrepreneur who contracted the Lyme Disease very early in her life, talks about her past struggles and how she had been successful in turning them into her strengths.
- New model from University of Illinois could help limit spread of Lyme diseaseon January 18, 2021 at 1:00 pm
A new model developed at the University of Illinois could help limit the spread of Lyme disease. Scientists at the University of Illinois Urbana-Champaign studied both reported cases of the disease as ...
- Lyme Disease May Be Far More Prevalent Than Thoughton January 15, 2021 at 8:35 am
Nearly 500,000 people are diagnosed with Lyme disease each year in the U.S., according to a new study from the CDC.
- 500K in U.S. diagnosed with Lyme disease annually, but some may not have iton January 13, 2021 at 2:36 pm
Roughly 500,000 people across the United States are diagnosed with Lyme disease each year, according to new estimates released Wednesday by the CDC, but researchers raise concern that some people may ...
- Lyme Disease More Common Than Previously Thoughton January 13, 2021 at 11:15 am
Between 2010 and 2018, the U.S. had approximately 476,000 cases of Lyme disease every year, according to a study out today from the Centers for Disease Control and Prevention (CDC). That number ...
- Porter County woman shares journey battling Lyme diseaseon January 8, 2021 at 6:00 am
Jessen has been confined to her bedroom, bedridden, with a view limited to the light green walls covered in her children's artwork.
- A New Look At Lyme Diseaseon January 5, 2021 at 7:44 pm
Lyme disease is a well-known infection caused by the bacterium Borrelia burgdorferi, typically communicated via a tick bite. Patients who suffer from Lyme disease frequently show symptoms such as a ...
- Single woman, 41, with Lyme Disease welcomes healthy baby into the world after going through IVF aloneon January 1, 2021 at 7:40 am
Julie Seal, 41, from Brockley, south east London, gave birth to Betsy who is in good health despite doctors warning her the child could contract Lyme disease at birth.
- Model predicts where Lyme disease-carrying ticks will developon December 21, 2020 at 4:00 pm
Dec. 22 (UPI) --A new model helps identify areas with high populations of the ticks that carry Lyme disease, a study published Tuesday by the Proceedings of the Royal Society B found. The ...
- Model predicts where ticks, Lyme disease will appear next in Midwest stateson December 21, 2020 at 4:00 pm
Black-legged ticks can carry the bacterium that causes Lyme disease, an infection that can affect the nervous system, heart and joints. The new model will help local authorities prepare for the ...
